Deborah A Young

US Patent:

7189400, Mar 13, 2007

Filed:

Oct 4, 2001

Appl. No.:

09/972218

Inventors:

Laura Carter - Medford MA, US
Matthew J. Whitters - Hudson MA, US
Mary Collins - Natick MA, US
Deborah A. Young - Melrose MA, US
Debra D. Donaldson - Medford MA, US
Lesile D. Lowe - Sudbury MA, US
Michelle Unger - Brighton MA, US

Assignee:

Genetics Institute, LLC - Cambridge MA

International Classification:

A61K 39/00
A61K 39/315
A61K 38/17

US Classification:

4241851, 4241431, 4241411, 4241921, 514 2, 514 12, 530350, 53038822, 536 235, 536 234

Abstract:

Provided is a method of suppressing an immune response in a subject by administering an antagonist of a MU-1 hematopoietin receptor superfamily chain protein.

US Patent:

7198789, Apr 3, 2007

Filed:

Oct 4, 2002

Appl. No.:

10/264634

Inventors:

Laura Carter - Medford MA, US
Beatriz Carreno - Acton MA, US
Leslie D. Lowe - Sudbury MA, US
Matthew J. Whitters - Hudson MA, US
Mary Collins - Natick MA, US
Margery Ma - W. Roxbury MA, US
Deborah A. Young - Melrose MA, US
JoAnn S. Witek - Acton MA, US
Glenn Larsen - Sudbury MA, US
Marion T. Kasaian - Charlestown MA, US
Debra D. Donaldson - Medford MA, US
Michelle Unger - Chapel Hill NC, US

Assignee:

Genetics Institute, LLC - Cambridge MA

International Classification:

A61K 39/00
A61K 39/395
A61K 38/17

US Classification:

4241301, 4241431, 4241411, 4241331, 4241351, 514 2, 530350, 53038822, 5303881, 5303871, 5303873, 5303879, 536 235

Abstract:

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e. g. , for treating or preventing immune cell-associated pathologies (e. g. , pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e. g. , as an adjuvant (e. g. , a vaccine adjuvant), to up-regulate an immune response in vivo, e. g. , for example, for use in treating cancer and infectious disorders.

US Patent:

7314623, Jan 1, 2008

Filed:

Jul 15, 2003

Appl. No.:

10/620169

Inventors:

Michael J. Grusby - Newton MA, US
Andrea Wurster - Arlington MA, US
Deborah Young - Melrose MA, US
Mary Collins - Natick MA, US
Matthew Whitters - Hudson MA, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 39/00
A61K 39/395
A61K 38/17

US Classification:

4241851, 4241431, 4241551, 514 2, 514 12

Abstract:

Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e. g. , human IL-21, activity or level.

US Patent:

7495085, Feb 24, 2009

Filed:

Mar 12, 2004

Appl. No.:

10/798380

Inventors:

Viia Valge-Archer - Little Abington, GB
Andrew James Williams - Royston, GB
Deborah A. Young - Melrose MA, US
Matthew J. Whitters - Hudson MA, US
Mary Collins - Natick MA, US
Joann Witek - Acton MA, US

Assignee:

Wyeth - Madison NJ
Cambridge Antibody Technology Limited - Cambridge

International Classification:

C07K 16/28
A61K 39/00
A61K 39/395
C12P 21/00

US Classification:

5303879, 53038823, 5303892, 5303913, 4241391, 4241431, 435 691

Abstract:

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.

US Patent:

7618632, Nov 17, 2009

Filed:

May 24, 2004

Appl. No.:

10/853032

Inventors:

Mary Collins - Natick MA, US
Ethan Menahem Shevach - Rockville MD, US
Rebecca Suzanne McHugh - Wellington, NZ
Matthew James Whitters - Hudson MA, US
Deborah Ann Young - Melrose MA, US
Michael Chapman Byrne - Brookline MA, US
Padmalatha S. Reddy - Walpole MA, US
Geoffrey Laurence Stephens - Damascus MD, US
Beatriz M. Carreno - Acton MA, US

Assignee:

Wyeth - Madison NJ
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/395
C07K 16/00

US Classification:

4241441, 53038822

Abstract:

The present invention provides novel isolated and purified polynucleotides and polypeptides related to a novel ligand for glucocorticoid-induced TNF receptor (GITR). The invention also provides antibodies to the GITR ligand (GITRL). The present invention also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating disorders arising from disregulation of the immune system (e. g. , autoimmune disorders, inflammatory diseases, and transplant rejection, and cancers and infectious diseases) using GITRL and/or modulators of GITRL. The present invention is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said disorders arising from disregulation of the immune system, as related to GITRL and GITR.

US Patent:

7731946, Jun 8, 2010

Filed:

Nov 12, 2007

Appl. No.:

11/938618

Inventors:

Michael J. Grusby - Newton MA, US
Andrea Wurster - Arlington MA, US
Deborah Young - Melrose MA, US
Mary Collins - Natick MA, US
Matthew Whitters - Hudson MA, US

Assignee:

Wyeth LLC - Madison NJ
The President and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 38/20
A61K 38/17
C07K 14/47

US Classification:

424 852, 424 851, 514 12, 514 2, 530351

Abstract:

Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e. g. , human IL-21, activity or level.

US Patent:

7910105, Mar 22, 2011

Filed:

Apr 13, 2006

Appl. No.:

11/402885

Inventors:

Deborah A. Young - Melrose MA, US
Thomas A. Wynn - Silver Spring MD, US
Mary Collins - Natick MA, US
Michael J. Grusby - Newton MA, US

Assignee:

Wyeth LLC - Madison NJ
The United States of America as represented by the Department of Health and Human Services - Washington DC
President and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 39/395
A61K 38/20

US Classification:

4241451, 514 12

Abstract:

The present invention provides methods of screening for compositions useful for treating, ameliorating, or preventing fibrosis and/or fibrosis-associated conditions by measuring changes in the level(s) of IL-21 and/or IL-21 receptor (IL-21R) (e. g. , the level of expression of IL-21 and/or IL-21R protein and/or mRNA, the level of activity of IL-21 and/or IL-21R, the level of interaction of IL-21 with IL-21R). The invention further provides antagonists of IL-21 or IL-21R for the treatment of fibrosis and/or fibrosis-associated conditions. Further provided herein are methods of diagnosing, prognosing, and monitoring the progress (e. g. , the course of treatment) of fibrosis and/or fibrosis-associated conditions by measuring the level of IL-21 and/or IL-21R (i. e. , the level of activity of IL-21 and/or IL-21R, the level of expression of IL-21 and/or IL-21R (e. g. , the level of IL-21 and/or IL-21R gene products), and/or the level of interaction of IL-21 with IL-21R).

US Patent:

8143385, Mar 27, 2012

Filed:

Jan 14, 2009

Appl. No.:

12/353812

Inventors:

Viia Valge-Archer - Little Abington, GB
Andrew James Williams - Royston, GB
Deborah A. Young - Melrose MA, US
Matthew J. Whitters - Hudson MA, US
Mary Collins - Natick MA, US
Joann Witek - Acton MA, US

Assignee:

Wyeth LLC - Madison NJ
MedImmune Ltd. - Cambridge

International Classification:

C07H 21/04
A61K 39/00
C12N 5/16
H01N 33/53

US Classification:

536 2353, 4241331, 4241351, 435 71, 435326, 435328, 435331, 436547

Abstract:

The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL-21R). The antibodies can act as antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, transplant rejection, cancer, and other immune system disorders.